Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Solid Tumor Clinical Trial

Official title:

A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03139370
• Other study ID #: KITE-718-301
• Secondary ID: 2020-005456-37
• Status: Terminated
• Phase: Phase 1
• Start date: December 27, 2017
• Est. completion date: June 4, 2023

Study information

• Verified date: August 2023
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.

Description:

Participants found to be human leukocyte antigen (HLA)-DPB1*04:01 positive and whose tumors are MAGE-A3 and/or MAGE-A6 positive can participate if all eligibility criteria are met. Other tests required to determine eligibility include a physical exam, electrocardiogram (ECG) and echocardiogram (ECHO) of the heart, CT or MRI scans, and blood draws. Eligible participants have white blood cells collected by leukapheresis. These cells are genetically modified to make the experimental treatment KITE-718. The desired outcome is that the genetically modified T cells will target tumor cells that express MAGE-A3 and/or MAGE-A6, which are proteins that can be expressed by cancer cells. Participants receive chemotherapy prior to the KITE-718 infusion. After the KITE-718 infusion, participants will be followed for side effects and have scans performed to see any potential impact on their cancers. Study procedures may be performed while hospitalized and/or in the outpatient setting. Subjects who received an infusion of KITE-718 will complete the remainder of the 15 year follow-up assessments in a separate long-term follow-up study, KT-US-982-5968

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 16
• Est. completion date: June 4, 2023
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Age = 18 years

• Advanced cancer defined as relapsed or refractory disease after a systemic standard of care treatment regimen and, if available, at least one standard of care salvage regimen unless the subject refuses such therapy. Multiple myeloma (MM) subjects must have had both a protease inhibitor (PI) and immunomodulatory drugs (IMiD) as part of the last regimen, or at least 3 prior lines of therapy, including a PI and an IMiD. Additionally, subjects must not have disease amenable to definitive locoregional therapy.

• MAGE-A3/A6 positive tumor as confirmed by the central laboratory

• HLA-DPB1*04:01 positive

• At least 1 measurable lesion on CT or MRI

• No evidence of central nervous system (CNS) disease by MRI or CT of the brain. Note:

Prior brain metastasis which have been treated with definitive therapy are eligible provided that the definitive therapy was completed more than six months prior to screening.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

• Toxicities due to prior therapy must be recovered to baseline or = grade 1, except for clinically non-significant toxicities such as alopecia

• Adequate bone marrow function as evidenced by:

• Absolute neutrophil count (ANC) = 1000/mm^3

• Platelet = 100/mm^3

• Hemoglobin > 8 g/dL

• Adequate renal, hepatic, cardiac, and pulmonary function as evidenced by:

• Creatinine clearance (as estimated by Cockcroft Gault) = 60 cc/min (24-hour urine creatinine clearance is also acceptable)

• Alanine transaminase (ALT)/aspartate aminotransferase (AST) = 2.5 x upper limit normal (ULN) or = 5 x ULN if documented liver metastases

• Total bilirubin = 1.5 mg/dL

• Cardiac ejection fraction = 50%, no evidence of pericardial effusion as determined by an ECHO, and no clinically significant ECG findings (For ejection fraction only, MUGA scan is also acceptable)

• No clinically significant pleural effusion

• Baseline oxygen saturation > 92% on room air

Key Exclusion Criteria:

• Malignancy other than non-melanoma skin cancer, carcinoma in situ, or low grade prostate cancer for which watch-and-wait approach is standard of care, unless disease free for at least 3 years

• Clinically significant cardiac disease within last 12 months

• Stroke or transient ischemic attack (TIA) within 12 last months

• Symptomatic deep vein thrombosis or pulmonary embolism within last 6 months, catheter associated thrombosis is not included as exclusion criteria.

• Prior T-cell therapy, including KITE-718 or MAGE-A3/A6-targeting therapy.

• Live vaccine = 4 weeks prior to enrollment

• Systemic corticosteroid therapy within 7 days before enrollment.

• History of severe, immediate hypersensitivity reaction attributed to aminoglycosides

• Presence of fungal, bacterial, viral, or other infection requiring IV antimicrobials for management.

• Presence of any indwelling line or drain. Note: Dedicated central venous access catheters such as a Port-a-Cath or Hickman catheter as well as feeding tubes such as a G-tube, are permitted.

• Primary immunodeficiency

• Autoimmune disease resulting in end-organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years prior to enrollment.

• Known history of infection with HIV, hepatitis B (HBsAg positive), or hepatitis C (anti-HCV positive). A history of treated hepatitis B or hepatitis C is permitted if the viral load is undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing.

• Females who are pregnant as confirmed by a positive serum or urine pregnancy test or are breastfeeding.

• Individuals of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KITE-718

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• KITE-718
A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).
• Cyclophosphamide
Administered intravenously
• Fludarabine
Administered intravenously

Device:
• MAGE - A3/A6 Screening Test
A screening test for MAGE-A3/A6+ tumors

Locations

Country	Name	City	State
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	University of Chicago	Chicago	Illinois
United States	Baylor Scott & White Charles A. Sammons Cancer Center	Dallas	Texas
United States	Banner MD Anderson Cancer Center	Gilbert	Arizona
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas
United States	UCLA Hematology/Oncology	Los Angeles	California
United States	USC/Norris Comprehensive Cancer Center	Los Angeles	California
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	University of California Davis Comprehensive Cancer Center	Sacramento	California
United States	University of Utah, Huntsman Cancer Institute	Salt Lake City	Utah
United States	H. Lee Moffitt Cancer and Research Institute	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Kite, A Gilead Company

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities	Dose-limiting toxicity is defined as protocol-defined KITE-718 related events with onset within the first 21 days following KITE-718 infusion.	Up to 21 days
Primary	Phase 1B - Efficacy: Objective Response Rate (ORR)	ORR is defined as complete response + partial response for participants evaluated by RECIST v1.1 and very good partial response (VGPR) or better for multiple myeloma participants evaluated by International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria.	Up to year 2 for solid tumor participants and up to Year 5 for multiple myeloma participants
Secondary	Duration of Response (DOR)	For participants who experience an objective response, DOR is defined as the time from the date of their first objective response to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death regardless of cause.	Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants
Secondary	Progression-Free Survival (PFS)	PFS is defined as the time from the KITE-718 infusion date to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death from any cause.	Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants
Secondary	Overall Survival	Overall survival is defined as the time from KITE-718 infusion to the date of death.	Up to 15 years
Secondary	Percentage of Participants Experiencing Adverse Events		Up to 15 years
Secondary	Percentage of Participants with Anti-KITE-718 Antibodies		Up to 2 years
Secondary	Percentage of Participants Experiencing Replication-competent Retrovirus (RCR)		Up to 2 years
Secondary	Levels of MAGE-A3/A6 TCR-transduced T Cells in Blood		Up to 2 years

External Links

•   Gilead Clinical Trials Website